ReviewFolia microbiologica2026
Silver nanoparticles in biomedicine: green synthesis, precision theranostics, and future clinical translation.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver nanoparticles (AgNPs) are widely explored in biomedical sciences due to their unique physicochemical properties and high surface reactivity, enabling diverse applications in diagnostics and therapeutics. This review highlights recent advances in the green synthesis of AgNPs and their biomedical relevance, with emphasis on translational potential. Biogenic synthesis of AgNPs using natural resources such as plant extracts offer eco-friendly and cost-effective alternatives, where bioactive phytochemicals contribute to the nanoparticle stabilization and functional properties. AgNPs have demonstrated potent antimicrobial, antiviral, anticancer, anti-inflammatory, and wound-healing activities, and their integration into targeted drug delivery and bioimaging platforms enhances therapeutic efficiency and disease monitoring. Advanced characterization techniques, have facilitated the understanding of AgNPs structure, morphology, and surface chemistry, enabling the design of application-specific AgNPs. Despite these advances, challenges including variability in synthesis, limited reproducibility, cytotoxicity, and uncertain biodistribution remain key barriers to clinical application. Addressing these limitations with emerging technologies such as artificial intelligence and machine learning could optimize their synthesis, predict biological interactions, and accelerate their translation to clinical applications. Overall, this review highlights that while green-synthesized AgNPs offer significant biomedical potential, improved standardization, safety evaluation, and translational strategies are essential for their successful clinical implementation.
Indexed as
Identifiers
42240937What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.